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Abstract Angiotensin II (Ang II) receptor subtypes AT1 and
AT2 share 34% overall homology, but the least homology is in
their third intracellular loop (3rd ICL). In an attempt to
elucidate the role of the 3rd ICL in determining the similarities
and differences in the functions of the AT1 and the AT2
receptors, we generated a chimeric receptor in which the 3rd ICL
of the AT2 receptor was replaced with that of the AT1 receptor.
Ligand-binding properties and signaling properties of this
receptor were assayed by expressing this receptor in Xenopus
oocytes. Ligand-binding studies using [125I-Sar1-Ile8] Ang II, a
peptidic ligand that binds both the AT1 and the AT2 receptor
subtypes, and 125I-CGP42112A, a peptidic ligand that is specific
for the AT2 receptor, showed that the chimeric receptor has lost
affinity to both ligands. However, IP3 levels of the oocytes
expressing the chimeric receptor were comparable to the IP3
levels of the oocytes expressing the AT1 receptor, suggesting that
the chimeric receptors could couple to phospholipase C pathway
in response to Ang II. We have shown previously that the nature
of the amino acid present in the position 215 located in the fifth
transmembrane domain (TMD) of the AT2 receptor plays an
important role in determining its affinity to different ligands. Our
results from the ligand-binding studies of the chimeric receptor
further support the idea that the structural organization of the
region spanning the 5th TMD and the 3rd ICL of the AT2
receptor has an important role in determining the ligand-binding
properties of this receptor.
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1. Introduction
Angiotensin II (Ang II), a multifunctional peptide, can act
as a hormone as well as a neurotransmitter ; it plays an im-
portant role in the regulation of blood pressure and body £uid
homeostasis [1^5]. As a potent vasoconstrictor hormone, Ang
II has been implicated in playing a crucial role in the patho-
genesis of hypertension, congestive heart failure and a number
of other related clinical conditions. The use of ACE inhibitors
such as captopril and enlapril (which prevent the formation of
Ang II) in the e¡ective treatment of many cardiovascular dis-
eases demonstrates the signi¢cance of the pathophysiological
role of Ang II in cardiovascular diseases [6,7]. Recently, it was
also demonstrated that Ang II increases the cerebral blood
£ow (CBF) during hypoxia in rabbits and that the ACE in-
hibitor captopril and the Ang II receptor antagonist saralasin
could inhibit this increase of CBF [8]. Ang II exerts its e¡ect
on a cell by binding to the Ang II speci¢c high a⁄nity recep-
tors present on the cell membrane, which initiates a speci¢c
signal transduction pathway.
High a⁄nity receptors implicated in mediating the e¡ects of
Ang II have been identi¢ed in a number of peripheral tissues,
such as those of the heart, mesenteric artery, aorta, adrenal
cortex, liver, uterus, bladder and pituitary. In the ovary, lo-
cally produced Ang II is suggested to play a role in oocyte
maturation [9^11]. In the brain, Ang II receptors are found
both inside and outside of the blood-brain barrier [12]. The
development of non-peptide receptor antagonists for Angio-
tensin II receptors has resulted in the discovery of Ang II
receptors with di¡erent pharmacological properties [13^16].
The Ang II receptor subtype having a high a⁄nity for losar-
tan has been designated AT1, and the other receptor subtype
with high a⁄nity for WL-19, EXP655, PD123319 and
CGP4212A has been designated AT2. The AT1 receptor is a
359 amino acid long protein and has two subtypes, AT1A and
AT1B (two subtypes are found in rat and mouse whereas only
one type is found in bovine, rabbit, pig, dog and human) [17^
24]. The AT2 receptor is a 363 amino acid long protein that
shares only 34% homology with the AT1 receptor [25,26].
These two receptor subtypes, AT1 and AT2, share structural
similarity in that both are proteins with seven transmembrane
topology. Upon activation by Ang II, these two receptor sub-
types are shown to exert synergistic e¡ects on certain cell
types and opposing e¡ects on other cell types. For example,
both AT1 and AT2 receptors induce activation of phospho-
lipase A2 and generation of arachidonic acid in cardiac myo-
cytes [27]. In contrast, while AT1 receptors induce cell prolif-
eration, AT2 receptors induce apoptosis or growth arrest
[28,29]. The responses induced by the cloned AT2 receptor
indicate sensitivity to pertussis toxin, suggesting that this re-
ceptor is a Gi-protein-coupled receptor. However, this recep-
tor does not demonstrate the GTPQS-induced shift to a low
a⁄nity form that is characteristic of the G-protein-linked re-
ceptors [25,26].
A comparison of the three intracellular loops of the AT1
and AT2 receptors had shown that homology is lowest in the
third intracellular loop of the AT2 receptor [25,26]. Recent
studies have also shown that introducing the synthetic intra-
cellular third loop peptide of the AT2 receptor into rat aortic
vascular smooth muscle cells resulted in partial inhibition of
the serum-induced DNA synthesis and proliferation in these
cells [30,31]. On the other hand, the third intracellular domain
of the AT1 receptor is shown to be essential for coupling of
this receptor to the Gq-protein and subsequent activation of
Phospholipase C [32]. To further elucidate the role of the third
intracellular loop in determining similarities and di¡erences
between the functions of the AT1 and AT2 receptors, we
generated a chimeric receptor in which the 3rd intracellular
loop (3rd ICL) of the AT2 was replaced with the amino acid
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sequence corresponding to the 3rd ICL of AT1. Here we re-
port the ligand-binding properties of this chimeric receptor
when it was expressed in Xenopus oocyte expression system.
2. Materials and methods
2.1. Materials
Radiolabeled material for sequencing and binding studies ([35S]-
dATP, [125I-Sar1-Ile8]Ang II, 125I-CGP42112A) were obtained from
Dupont NEN (Boston, MA, USA). Restriction enzymes were pur-
chased either from Boehringer Mannheim (Indianapolis, IN, USA)
or from Promega (Madison, WI, USA). Oligonucleotides used for
sequencing and mutagenesis were purchased from GIBCO BRL Life
Technologies Inc. (Gaithersburey, MD, USA). The kits that were used
in this study were, DTth DNA Polymerase Sequencing Kit (Clon-
Tech, Palo Alto, CA, USA), Quick Change site-directed mutagenesis
kit (Stratagene Products, La Jolla, CA, USA), and Riboprobe Gemini
in vitro transcription system (Promega, Madison, WI, USA). Xenopus
laevis were obtained from Xenopus One (Ann Arbor, MI, USA).
2.2. Construction of the chimeric receptor
This was done by using the ‘sticky-feet PCR mutagenesis’ method
[33]. The DNA fragments encoding the open reading frames of the
AT1 and the AT2 receptor genes were cloned in the plasmid pSP64-
polyA previously [34]. Oligonucleotide primers carrying combinations
of the AT2 and AT1 receptor sequences were used for this purpose.
The ¢rst primer was 5P-AGCAACGTGTTACTTTGGAATCTGGA-
AAGCTCTAAAGAAGGCT-3P ; in this primer the ¢rst 22 nucleoti-
des corresponded to that of the DNA sequence at the 3P side of the
¢fth transmembrane domain of the AT2 receptor. The next 21 nucleo-
tides corresponded to the 5P side of the third intracellular loop of the
AT1 receptor. The second primer was 5P-GCCAACACAACAGCA-
GCTGCCATCCTAAAGATGTCATCGTTTCT-3P. In this primer
the ¢rst 23 nucleotides were complimentary to the 5P side of the sixth
transmembrane domain of the AT2 receptor. The next 21 nucleotides
were complimentary to the DNA sequence at the 3P side of the third
intracellular loop of the AT1 receptor. The ¢rst step was to PCR
amplify the third intracellular loop of the AT1 receptor using these
primers and the AT1 receptor gene as template by PCR ampli¢cation.
The ampli¢ed DNA fragments were then used as ‘sticky-feet primers’
(since they carried the entire third intracellular loop of the AT1 re-
ceptor and sequences corresponding to the ¢fth and sixth transmem-
brane domains of the AT2 receptor) to perform PCR mutagenesis of
the AT2 receptor gene clone in the plasmid pSP64polyA. PCR muta-
genesis was carried out using Quick Change site-directed mutagenesis
kit (Stratagene Products, La Jolla, CA, USA). The sequence of the
mutant was veri¢ed by nucleotide sequencing with dideoxy chain ter-
mination method [35]. The plasmid carrying the DNA fragment en-
coding the chimeric receptor was designated pBG899. In vitro tran-
scription to generate cRNAs encoding the wild-type and chimeric
receptors were carried out as described previously [34]. Microinjection
of Xenopus oocytes and ligand-binding experiments also were per-
formed as described previously [34].
2.3. Measurement of IP3 levels
IP3 measurements were carried out according to the protocols of
the ‘Inositol-1-4-5-trisphosphate [3H] radio receptor kit’ purchased
from DuPont NEN. Groups of ¢ve oocytes were exposed to 100 nM
Ang II for 5 min and were frozen immediately in liquid nitrogen.
Experiments were done in triplicates for the oocytes isolated from
each frog. Thus, ¢ve oocytes were used to generate one sample (about
200 Wl of cytosol is obtained after extraction according to the proce-
dure of RIA kit) for IP3 measurement and from each sample, dupli-
cates (100 Wl each) were used to measure IP3 levels according to the
RIA kit.
3. Results and discussion
3.1. Ligand-binding properties of the chimeric receptor
Amino acid sequence of the chimeric receptor is shown in
Fig. 1. In an attempt to understand the contribution of the
third intracellular loop (3rd ICL) in determining the similar-
ities and di¡erences in the functions of the AT1 and AT2
receptors, we compared the ligand-binding properties of the
Xenopus oocytes expressing the cRNAs encoding the wild-type
AT2 receptor and the chimeric AT2 receptor. The ligands
used in this study were [125I-Sar1-Ile8] Ang II, a peptidic
ligand that binds both the AT1 and the AT2 receptor sub-
types, and 125I-CGP42112A, a peptidic ligand that is speci¢c
for the AT2 receptor. It was observed that the oocytes ex-
pressing the chimeric receptor showed highly reduced binding
to both peptidic ligands [125I-Sar1-Ile8] Ang II and 125I-labeled
CGP42112A (Fig. 2). It was reported that the amino acids
located at the amino-terminus of the AT2 receptor and the
3rd transmembrane domain of the AT2 receptor may directly
interact with Angiotensin II during its binding [36]. Therefore,
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Fig. 1. Amino acid sequence and the predicted organization of the chimeric receptor generated by replacing the 3rd intracellular loop (ICL) of
the AT2 receptor with that of the AT1 receptor. The amino acid sequence of the third ICL corresponds to that of the AT1 receptor and is
marked by circles with no ¢lling. PCR mutagenesis resulted in replacing the 9th amino acid from the amino-terminal region of the 3rd ICL,
Glutamic acid, with Valine. However, this mutation did not seem to a¡ect the ability of the receptor to activate phospholipase C pathway as
determined by measuring the intracellular IP3 levels.
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we did not anticipate that replacing the 3rd ICL of the AT2
receptor with that of the AT1 would a¡ect the ligand-binding
properties of the chimeric receptor considerably. However,
results of our ligand-binding experiments using 125I-labeled
peptidic ligands indicated that structural organization of the
region spanning the 5th transmembrane domain and the 3rd
ICL of the AT2 receptor may play an important role in de-
termining the ligand-binding properties of the AT2 receptor.
Moreover, previously we have shown that the high a⁄nity
form of the AT2 receptor that binds the [125I-Sar1-Ile8] Ang
II is di¡erent from that which is needed to bind the 125I-
CGP42112A [34]. This was based on the observation that
replacing the Lys215 located on the ¢fth transmembrane do-
main of the AT2 receptor with Glu or Gln resulted in gener-
ating AT2 receptors that could bind 125I-CGP42112A with
high a⁄nity, but could not bind [125I-Sar1-Ile8] Ang II. How-
ever, replacing the 3rd ICL of the AT2 receptor resulted in
reducing the high a⁄nity of the AT2 receptor to both ligands.
Thus it seems that the 3rd ICL of the AT2 receptor is not only
essential for coupling the receptor to its signal transducers,
but also is necessary for maintaining the high a⁄nity li-
gand-binding form of this receptor.
3.2. Coupling of the chimeric receptor to Phospholipase C
pathway
Since the Xenopus oocytes expressing the chimeric receptor
were unable to bind ligands [125I-Sar1-Ile8] Ang II and 125I-
CGP42112A, it was necessary to ensure that the oocytes were
capable of expressing the mutated receptor. It was shown
previously that the 3rd ICL of the AT1 receptor is essential
for the coupling of this receptor to Phospholipase C pathway
upon Ang II binding. Therefore, in analyzing to see if the
Xenopus oocytes microinjected with the chimeric receptor
were indeed expressing this receptor, we compared the intra-
cellular IP3 levels of the oocytes microinjected with equal
amounts of cRNAs encoding either the AT1 receptor or the
chimeric receptor after exposing them to Ang II. Groups of
¢ve oocytes were exposed to Ang II and the intracellular IP3
levels were measured using the ‘Inositol-1-4-5-trisphosphate
[3H] radio receptor kit’ purchased from DuPont NEN. As
shown in Fig. 3, the intracellular IP3 levels of oocytes express-
ing the chimeric receptor and exposed to Ang II were elevated
to similar extents as seen in the oocytes expressing the AT1A
receptor. This result implied that the chimeric receptor was
expressed by the oocytes and it was indeed functional,
although this expression could not be detected in radiolabeled
ligand-binding experiments. Thus, the chimeric receptor mim-
FEBS 21557 19-2-99
Fig. 3. Intracellular IP3 levels of the oocytes expressing the chimeric
receptor and exposed to 1 mM of Ang II. IP3 measurements were
carried out according to the protocols of the ‘Inositol-1-4-5-trisphos-
phate [3H] radio receptor kit’ purchased from DuPont NEN. Five
oocytes were used to generate one sample (about 200 Wl of cytosole
is obtained after extraction according to the procedure of RIA kit)
for IP3 measurement and from each sample duplicates (100 Wl each)
were used to measure IP3 levels according to the RIA kit. Oocytes
from three di¡erent frogs were used and two di¡erent cRNA prepa-
rations were used. Standard deviation for the IP3 levels (in pico-
moles) of the oocytes expressing rAT1A was þ 1.8, for chimeric re-
ceptor was þ 1.6 and for uninjected was þ 0.76.
Fig. 2. Ligand-binding properties of the chimeric receptor. Comparison of the speci¢c binding of the [125I-Sar1-Ile8] Ang II (0.5 nM) and
125I-CGP42112A (0.25 nM) to the oocytes expressing wild-type and chimeric receptor. Binding experiments were conducted for a period of 1 h
according to the procedures described previously [34]. Results are shown as relative % of the binding of the appropriate ligand to the oocytes
expressing wild-type AT2 receptor. Receptor expression was quantitated by binding studies using four to seven oocytes from at least three do-
nors (a total of at least 12 oocytes). Three di¡erent cRNA preparations were used for each sample. Standard errors were within 5% of each
value.
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icked the rAT1 receptor in its ability to activate the phospho-
lipase C pathway. The inability of the chimeric receptor to
bind peptidic ligands [125I-Sar1-Ile8] Ang II and 125I-
CGP42112A was particularly interesting, since a mutation at
the intracellular domain has resulted in changing the binding
properties of the receptor signi¢cantly.
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